Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
- DOI
- 10.1182/blood-2005-07-2947
- Published
- 2006-06-01
- Container
- Blood
- Publisher
- American Society of Hematology
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1182/blood-2005-07-2947,
title = {Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction},
author = {Mhairi Copland and Ashley Hamilton and Lucy J. Elrick and Janet W. Baird and Elaine K. Allan and Niove Jordanides and Martin Barow and Joanne C. Mountford and Tessa L. Holyoake},
year = {2006},
journal = {Blood},
doi = {10.1182/blood-2005-07-2947},
url = {https://doi.org/10.1182/blood-2005-07-2947}
}RIS
TY - JOUR TI - Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction AU - Mhairi Copland AU - Ashley Hamilton AU - Lucy J. Elrick AU - Janet W. Baird AU - Elaine K. Allan AU - Niove Jordanides AU - Martin Barow AU - Joanne C. Mountford AU - Tessa L. Holyoake PY - 2006 JO - Blood DO - 10.1182/blood-2005-07-2947 UR - https://doi.org/10.1182/blood-2005-07-2947 ER -
APA
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. https://doi.org/10.1182/blood-2005-07-2947
Source records
- crossref · retrieved 2026-09-26T02:46:13.196Z